Group 1 - The core point of the announcement is that Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the drug GB10 injection [1][2] Group 2 - The GB10 injection is a high-concentration ophthalmic protein drug formulation developed independently by Shenzhen Kexing, targeting both VEGF and Ang-2, with a concentration of 140 mg/mL, which is expected to improve patient compliance by allowing administration every four months [3] - Preclinical data indicates that GB10 injection's biological activity and animal efficacy meet international competitive standards, effectively inhibiting choroidal neovascularization in monkey models [3] Group 3 - The approval for the clinical trial of GB10 injection is a significant milestone in the company's innovative drug development process, marking key progress in its dual-antibody research strategy based on its proprietary technology platform [4] - If successfully developed and launched, GB10 injection could diversify the company's product offerings and enhance its market competitiveness [4]
科兴生物制药股份有限公司 自愿披露关于眼科制剂GB10注射液获得药物临床试验批准通知书的公告